• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma: An ALTAIR Trial Report.

作者信息

Sugizaki Yoichiro, Otake Hiromasa, Kawamori Hiroyuki, Toba Takayoshi, Nagano Yuichiro, Tsukiyama Yoshiro, Yanaka Ken-Ichi, Yamamoto Hiroyuki, Nagasawa Akira, Onishi Hiroyuki, Takeshige Ryo, Nakano Shinsuke, Matsuoka Yoichiro, Tanimura Kosuke, Takahashi Yu, Fukuyama Yusuke, Shinke Toshiro, Ishida Tatsuro, Hirata Ken-Ichi

出版信息

JACC Cardiovasc Imaging. 2020 Jun;13(6):1452-1454. doi: 10.1016/j.jcmg.2020.01.021. Epub 2020 Mar 18.

DOI:10.1016/j.jcmg.2020.01.021
PMID:32199850
Abstract
摘要

相似文献

1
Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma: An ALTAIR Trial Report.在瑞舒伐他汀基础上加用阿利西尤单抗有助于降低薄帽纤维粥样斑块的易损性：一项ALTAIR试验报告。
JACC Cardiovasc Imaging. 2020 Jun;13(6):1452-1454. doi: 10.1016/j.jcmg.2020.01.021. Epub 2020 Mar 18.
2
Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.阿利西尤单抗降低斑块易损性的疗效：在接受瑞舒伐他汀治疗的日本冠心病患者中进行的一项随机对照试验（ALTAIR 研究）的研究方案。
J Cardiol. 2019 Mar;73(3):228-232. doi: 10.1016/j.jjcc.2018.11.012. Epub 2018 Dec 19.
3
Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study.高强度他汀治疗急性心肌梗死患者的冠状动脉斑块成分变化（IBIS-4）：一项连续光学相干断层扫描研究。
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1518-1528. doi: 10.1016/j.jcmg.2018.08.024. Epub 2018 Dec 12.
4
Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.PCSK9 抗体阿利西尤单抗对急性心肌梗死患者冠状动脉粥样硬化的影响：一项连续多血管血管内超声、近红外光谱和光相干断层成像研究——PACMAN-AMI 试验的原理和设计。
Am Heart J. 2021 Aug;238:33-44. doi: 10.1016/j.ahj.2021.04.006. Epub 2021 May 2.
5
Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.Alirocumab 对急性冠状动脉综合征日本患者冠状动脉粥样斑块体积的影响 - ODYSSEY J-IVUS 试验。
Circ J. 2019 Sep 25;83(10):2025-2033. doi: 10.1253/circj.CJ-19-0412. Epub 2019 Aug 20.
6
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.在接受和不接受阿托伐他汀治疗的高胆固醇血症患者中单次和多次给予 bococizumab（一种人源化 IgG2Δa 单克隆抗体，与前蛋白转化酶枯草溶菌素/糜蛋白酶 9 结合）的效果：四项 I 期研究的结果。
Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.
7
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.在高剂量他汀类药物治疗的高胆固醇血症患者中，静脉注射阻断前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 的人源化单克隆抗体 Bocizumab 治疗 12 周的效果。
Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12308. Epub 2017 Nov 25.
8
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.在极高危患者中，低密度脂蛋白胆固醇水平较低与心血管事件之间的关联：依洛尤单抗与对照的 9 项 ODYSSEY 试验的汇总分析。
Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.
9
Alirocumab as add-on therapy to statins: current evidence and clinical potential.阿利西尤单抗作为他汀类药物的附加疗法：当前证据及临床潜力。
Ther Adv Cardiovasc Dis. 2018 Jul;12(7):191-202. doi: 10.1177/1753944718775352. Epub 2018 May 24.
10
Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent.在接受依维莫司洗脱支架治疗的稳定型冠状动脉疾病中，强化他汀治疗可使C反应蛋白稳定，但对趋化因子无此作用。
Coron Artery Dis. 2016 Aug;27(5):405-11. doi: 10.1097/MCA.0000000000000375.

引用本文的文献

1
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis.前蛋白转化酶枯草溶菌素/克新9型抑制剂联合他汀类药物治疗对慢性/急性冠状动脉综合征患者冠状动脉斑块消退的多模态评估：一项荟萃分析。
J Int Med Res. 2025 Aug;53(8):3000605251361962. doi: 10.1177/03000605251361962. Epub 2025 Aug 5.
2
Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography.依洛尤单抗对冠状动脉斑块成分及微钙化活性的影响：冠状动脉PET及CT血管造影研究
JACC Cardiovasc Imaging. 2025 May;18(5):589-599. doi: 10.1016/j.jcmg.2025.01.005. Epub 2025 Apr 2.
3
Assessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial.评估阿利西尤单抗对极高风险动脉粥样硬化性心血管疾病患者薄帽纤维粥样斑块和内皮功能的影响：一项随机对照试验的研究方案
Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1236-1246. doi: 10.21037/cdt-24-336. Epub 2024 Dec 19.
4
Plaque Stabilization and Regression, from Mechanisms to Surveillance and Clinical Strategies.斑块稳定与逆转：从机制到监测及临床策略
Rev Cardiovasc Med. 2024 Dec 25;25(12):459. doi: 10.31083/j.rcm2512459. eCollection 2024 Dec.
5
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes.急性冠状动脉综合征患者中9型前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶抑制剂：从降脂、斑块稳定到改善预后
J Clin Med. 2024 Aug 25;13(17):5040. doi: 10.3390/jcm13175040.
6
Emerging Hybrid Intracoronary Imaging Technologies and Their Applications in Clinical Practice and Research.新兴的冠状动脉混合成像技术及其在临床实践和研究中的应用。
JACC Cardiovasc Interv. 2024 Sep 9;17(17):1963-1979. doi: 10.1016/j.jcin.2024.07.007.
7
Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression.降脂治疗对动脉粥样硬化性冠状动脉斑块的消退作用：一项荟萃分析和元回归分析
Am J Prev Cardiol. 2024 Mar 11;18:100645. doi: 10.1016/j.ajpc.2024.100645. eCollection 2024 Jun.
8
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature.PCSK9 靶向治疗的长期疗效和耐受性：文献综述。
Drugs. 2024 Feb;84(2):165-178. doi: 10.1007/s40265-024-01995-9. Epub 2024 Jan 25.
9
Effects of Lipid Lowering Therapies on Vulnerable Plaque Features: An Updated Narrative Review of the Literature.降脂疗法对易损斑块特征的影响：文献的最新叙述性综述
J Cardiovasc Dev Dis. 2023 Jun 15;10(6):260. doi: 10.3390/jcdd10060260.
10
PCSK9 inhibitors for acute coronary syndrome: the era of early implementation.用于急性冠状动脉综合征的前蛋白转化酶枯草溶菌素9抑制剂：早期应用时代
Front Cardiovasc Med. 2023 May 2;10:1138787. doi: 10.3389/fcvm.2023.1138787. eCollection 2023.